The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Oncol.
Sec. Radiation Oncology
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1395824
Baseline and interim 18F-FDG PET/CT metabolic parameters predict the efficacy and survival in patients with diffuse large B-cell lymphoma
Provisionally accepted
CHENGCHENG LIAO
1*
Qifeng Deng
1
Lin Zeng
1*
Baoping Guo
1*
Zhe Li
1*
Da Zhou
1*
Qing Ke
1*
Mingyue Wang
1*
Mei Huang
2*
Xiaohong Tan
1*
Hong Cen
1*- 1 Guangxi Medical University Cancer Hospital, Nanning, Guangxi Zhuang Region, China
- 2 Guangxi Medical University, Nanning, Guangxi Zhuang Region, China
The 18 F-fluorodeoxy glucose positron emission tomography/computed tomog-20 raphy( 18 F-FDG PET/CT) is widely used to stage and monitor treatment responses in patien 21 -ts with diffuse large B-cell lymphoma (DLBCL). However, the predictive ability of 18 F-FDG 22 PET/CT metabolic parameters varies across studies. In this study, the third quartile of liver u 23 -ptake values was used as a threshold to measure metabolic tumor volume (MTV) and total 24 lesion glycolysis (TLG) in patients both before and after 3-4 cycles of R-CHOP treatment. Thi 25 -s study aimed to explore the correlation between MTV and TLG and the prognosis of patie-26 nts with diffuse large B-cell lymphoma. The results indicate that TLG may be able to disting 27 -uish patients with poor prognosis among those with Ann Arbor staging of stage I-II, and Δ 28 -TLG may distinguish patients with good prognosis among those with 5-PS score >3.
Keywords: Diffuse large B-cell lymphoma, 18 F-FDG PET/CT, Total lesion glycolysis, metabolic tumor volume, prognostic factors analysis
Received: 05 Mar 2024; Accepted: 16 Sep 2024.
Copyright: © 2024 LIAO, Deng, Zeng, Guo, Li, Zhou, Ke, Wang, Huang, Tan and Cen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
CHENGCHENG LIAO, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi Zhuang Region, China
Lin Zeng, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi Zhuang Region, China
Baoping Guo, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi Zhuang Region, China
Zhe Li, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi Zhuang Region, China
Da Zhou, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi Zhuang Region, China
Qing Ke, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi Zhuang Region, China
Mingyue Wang, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi Zhuang Region, China
Mei Huang, Guangxi Medical University, Nanning, 530021, Guangxi Zhuang Region, China
Xiaohong Tan, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi Zhuang Region, China
Hong Cen, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi Zhuang Region, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.